JP2009538852A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009538852A5 JP2009538852A5 JP2009512481A JP2009512481A JP2009538852A5 JP 2009538852 A5 JP2009538852 A5 JP 2009538852A5 JP 2009512481 A JP2009512481 A JP 2009512481A JP 2009512481 A JP2009512481 A JP 2009512481A JP 2009538852 A5 JP2009538852 A5 JP 2009538852A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- methyl
- pyrido
- imidazo
- pyrazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 45
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 35
- 208000035475 disorder Diseases 0.000 claims 34
- 229910052736 halogen Inorganic materials 0.000 claims 27
- 150000002367 halogens Chemical group 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 25
- 125000004122 cyclic group Chemical group 0.000 claims 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 16
- -1 di-C 1-3 alkylamino Chemical group 0.000 claims 15
- 208000028017 Psychotic disease Diseases 0.000 claims 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 10
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 8
- 201000000980 schizophrenia Diseases 0.000 claims 8
- 230000003542 behavioural effect Effects 0.000 claims 7
- 206010026749 Mania Diseases 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 208000010877 cognitive disease Diseases 0.000 claims 5
- 208000028698 Cognitive impairment Diseases 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000002085 persistent effect Effects 0.000 claims 4
- 208000022821 personality disease Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 208000012661 Dyskinesia Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 3
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Natural products C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 3
- 230000036630 mental development Effects 0.000 claims 3
- 230000036651 mood Effects 0.000 claims 3
- 230000000926 neurological effect Effects 0.000 claims 3
- 208000020016 psychiatric disease Diseases 0.000 claims 3
- 230000001107 psychogenic effect Effects 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims 2
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000024254 Delusional disease Diseases 0.000 claims 2
- 206010012559 Developmental delay Diseases 0.000 claims 2
- 208000014094 Dystonic disease Diseases 0.000 claims 2
- 208000027534 Emotional disease Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010021030 Hypomania Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 2
- 206010036790 Productive cough Diseases 0.000 claims 2
- 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 208000010118 dystonia Diseases 0.000 claims 2
- 230000008451 emotion Effects 0.000 claims 2
- 230000002140 halogenating effect Effects 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000000698 schizophrenic effect Effects 0.000 claims 2
- 208000024794 sputum Diseases 0.000 claims 2
- 210000003802 sputum Anatomy 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- XSUZWGLUKSVWPV-UHFFFAOYSA-N 13-(2-chlorophenyl)-4-methoxy-11-methyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraen-10-amine Chemical compound C=1N(OC)CN2C=1C=NC(C(=C(C)C1)N)=C2N1C1=CC=CC=C1Cl XSUZWGLUKSVWPV-UHFFFAOYSA-N 0.000 claims 1
- KBCZMCBZVDVOGT-UHFFFAOYSA-N 13-ethyl-4-(2-ethyl-4-methylimidazol-1-yl)-11-methyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraen-10-amine Chemical compound CCN1CC(C)=C(N)C(N=CC2=C3)=C1N2CN3N1C=C(C)N=C1CC KBCZMCBZVDVOGT-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- SDIVRNMOSXJHJF-UHFFFAOYSA-N 4-hydroxy-10-imidazol-1-yl-11-methyl-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene 4-methoxy-11-methyl-10-(2-methylimidazol-1-yl)-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene Chemical compound N12CN(O)C=C2C=NC2=C1N(CCC)CC(C)=C2N1C=CN=C1.N12CN(OC)C=C2C=NC2=C1N(CCC)CC(C)=C2N1C=CN=C1C SDIVRNMOSXJHJF-UHFFFAOYSA-N 0.000 claims 1
- PKVOCTCUKPQTPD-UHFFFAOYSA-N 4-methoxy-11-methyl-13-propyl-10-pyrazol-1-yl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene Chemical compound N12CN(OC)C=C2C=NC2=C1N(CCC)CC(C)=C2N1C=CC=N1 PKVOCTCUKPQTPD-UHFFFAOYSA-N 0.000 claims 1
- SAFWDYDJJSDWKS-UHFFFAOYSA-N 4-methoxy-13-propan-2-yl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraen-10-amine Chemical compound CC(C)N1CC=C(N)C2=C1N1CN(OC)C=C1C=N2 SAFWDYDJJSDWKS-UHFFFAOYSA-N 0.000 claims 1
- 208000017194 Affective disease Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000036640 Asperger disease Diseases 0.000 claims 1
- 201000006062 Asperger syndrome Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 206010006362 Brief psychotic disorder, with postpartum onset Diseases 0.000 claims 1
- WOZIJLOUMFUAHG-UHFFFAOYSA-N C(=O)NC1=C(CN(C2=C1N=CC=1N2CN(C1)OC)CCC)C.C(C)N1CC(=C(C=2N=CC=3N(C21)CN(C3)OC)NC=O)C Chemical compound C(=O)NC1=C(CN(C2=C1N=CC=1N2CN(C1)OC)CCC)C.C(C)N1CC(=C(C=2N=CC=3N(C21)CN(C3)OC)NC=O)C WOZIJLOUMFUAHG-UHFFFAOYSA-N 0.000 claims 1
- ZEEHWDBOQFHNPI-UHFFFAOYSA-N C1(CC1)N(C1=C(CN(C2=C1N=CC=1N2CN(C1)OC)CCC)C)C(=O)O.CON1CN2C(C=NC3=C2N(CC(=C3NC(CC)=O)C)CCC)=C1 Chemical compound C1(CC1)N(C1=C(CN(C2=C1N=CC=1N2CN(C1)OC)CCC)C)C(=O)O.CON1CN2C(C=NC3=C2N(CC(=C3NC(CC)=O)C)CCC)=C1 ZEEHWDBOQFHNPI-UHFFFAOYSA-N 0.000 claims 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 1
- AOBXKNBWKZNMDM-UHFFFAOYSA-N CON1CN2C(C=NC3=C2N(CC(=C3N3N=CN=C3)C)CCC)=C1.CON1CN3C(C=NC2=C3N(CC(=C2N2N=NC=C2)C)CCC)=C1 Chemical compound CON1CN2C(C=NC3=C2N(CC(=C3N3N=CN=C3)C)CCC)=C1.CON1CN3C(C=NC2=C3N(CC(=C2N2N=NC=C2)C)CCC)=C1 AOBXKNBWKZNMDM-UHFFFAOYSA-N 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 206010012239 Delusion Diseases 0.000 claims 1
- 208000012239 Developmental disease Diseases 0.000 claims 1
- 208000005819 Dystonia Musculorum Deformans Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000008967 Enuresis Diseases 0.000 claims 1
- 206010015605 Excessive masturbation Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000001836 Firesetting Behavior Diseases 0.000 claims 1
- 206010016717 Fistula Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 1
- 208000030979 Language Development disease Diseases 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- YLVZSXRBQSXTCU-UHFFFAOYSA-N N-(13-ethyl-4-methoxy-11-methyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraen-10-yl)acetamide Chemical compound N12CN(OC)C=C2C=NC2=C1N(CC)CC(C)=C2NC(C)=O YLVZSXRBQSXTCU-UHFFFAOYSA-N 0.000 claims 1
- WFXOQXUOONKIEU-UHFFFAOYSA-N N-acetyl-N-(4-methoxy-11-methyl-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraen-10-yl)acetamide N-(4-methoxy-11-methyl-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraen-10-yl)acetamide Chemical compound N12CN(OC)C=C2C=NC2=C1N(CCC)CC(C)=C2NC(C)=O.N12CN(OC)C=C2C=NC2=C1N(CCC)CC(C)=C2N(C(C)=O)C(C)=O WFXOQXUOONKIEU-UHFFFAOYSA-N 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- FWSWXDRCGPVIKS-UHFFFAOYSA-N NC1=C(CN(C2=C1N=CC=1N2C=NC1)CCC)C.NC1=C(CN(C2=C1N=CC=1N2C=NC1)CC)C Chemical compound NC1=C(CN(C2=C1N=CC=1N2C=NC1)CCC)C.NC1=C(CN(C2=C1N=CC=1N2C=NC1)CC)C FWSWXDRCGPVIKS-UHFFFAOYSA-N 0.000 claims 1
- UCJJLDNDXVAYLU-UHFFFAOYSA-N NC1=C(CN(C2=C1N=CC=1N2CN(C1)OC)CC)C.NC1=C(CN(C2=C1N=CC=1N2CN(C1)OC)CCC)C Chemical compound NC1=C(CN(C2=C1N=CC=1N2CN(C1)OC)CC)C.NC1=C(CN(C2=C1N=CC=1N2CN(C1)OC)CCC)C UCJJLDNDXVAYLU-UHFFFAOYSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 206010029333 Neurosis Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000012202 Pervasive developmental disease Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 101710122057 Phospholemman-like protein Proteins 0.000 claims 1
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims 1
- 208000022372 Reading disease Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 206010039987 Senile psychosis Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000027520 Somatoform disease Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000006978 adaptation Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000016571 aggressive behavior Effects 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 229960001948 caffeine Drugs 0.000 claims 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 1
- 229930003827 cannabinoid Natural products 0.000 claims 1
- 239000003557 cannabinoid Substances 0.000 claims 1
- 229940065144 cannabinoids Drugs 0.000 claims 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims 1
- 206010007776 catatonia Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 150000001805 chlorine compounds Chemical group 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 231100000868 delusion Toxicity 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 208000018459 dissociative disease Diseases 0.000 claims 1
- 206010013932 dyslexia Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002996 emotional effect Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000003890 fistula Effects 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 239000000380 hallucinogen Substances 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 208000012198 paraphilic disease Diseases 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 208000021011 postpartum psychosis Diseases 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 229940124811 psychiatric drug Drugs 0.000 claims 1
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 208000022610 schizoaffective disease Diseases 0.000 claims 1
- 201000002899 segmental dystonia Diseases 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 208000027765 speech disease Diseases 0.000 claims 1
- 208000013623 stereotypic movement disease Diseases 0.000 claims 1
- 239000000021 stimulant Substances 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 208000018724 torsion dystonia Diseases 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 0 *c(nc1I)c2[n]1c1nc(*)ccc1nc2* Chemical compound *c(nc1I)c2[n]1c1nc(*)ccc1nc2* 0.000 description 4
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80925106P | 2006-05-30 | 2006-05-30 | |
| PCT/EP2007/004747 WO2007137819A1 (en) | 2006-05-30 | 2007-05-29 | 4-AMINO-PYRIDO[3,2-e]PYRAZINES, THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10, AND PROCESSES FOR PREPARING THEM |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009538852A JP2009538852A (ja) | 2009-11-12 |
| JP2009538852A5 true JP2009538852A5 (OSRAM) | 2010-07-15 |
Family
ID=38441601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009512481A Pending JP2009538852A (ja) | 2006-05-30 | 2007-05-29 | ４−アミノ−ピリド［３，２−ｅ］ピラジン、該化合物のホスホジエステラーゼ１０の阻害剤としての使用、及び該化合物の製造方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20070299079A1 (OSRAM) |
| EP (1) | EP2021341A1 (OSRAM) |
| JP (1) | JP2009538852A (OSRAM) |
| CN (1) | CN101448829A (OSRAM) |
| AR (1) | AR060984A1 (OSRAM) |
| AU (1) | AU2007267391A1 (OSRAM) |
| BR (1) | BRPI0711857A2 (OSRAM) |
| CA (1) | CA2653412A1 (OSRAM) |
| CL (1) | CL2007001555A1 (OSRAM) |
| MX (1) | MX2008015308A (OSRAM) |
| PE (1) | PE20080266A1 (OSRAM) |
| TW (1) | TW200815436A (OSRAM) |
| WO (1) | WO2007137819A1 (OSRAM) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008072779A1 (ja) | 2006-12-13 | 2008-06-19 | Aska Pharmaceutical Co., Ltd. | キノキサリン誘導体 |
| WO2009068246A2 (en) * | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Methods of treating obesity and metabolic disorders |
| WO2009070583A1 (en) * | 2007-11-30 | 2009-06-04 | Wyeth | Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10 |
| EP2225248A1 (en) * | 2007-11-30 | 2010-09-08 | Wyeth LLC | Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10 |
| WO2010054260A1 (en) * | 2008-11-07 | 2010-05-14 | Biotie Therapies Gmbh | Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases |
| NZ603789A (en) | 2010-05-26 | 2015-03-27 | Sunovion Pharmaceuticals Inc | Heteroaryl compounds and methods of use thereof |
| DE102010042833B4 (de) | 2010-10-22 | 2018-11-08 | Helmholtz-Zentrum Dresden - Rossendorf E.V. | Neue Halogenalkoxychinazoline, deren Herstellung und Verwendung |
| US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
| MX2013009575A (es) | 2011-02-18 | 2014-10-14 | Exonhit Therapeutics Sa | Derivados de 6, 7-dialcoxi-3-isoquinolinol sustituidos como inhibidores de fosfodiesterasa 10 (pdei0a). |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| US9056863B2 (en) * | 2011-09-09 | 2015-06-16 | H. Lundbeck A/S | Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof |
| HK1211023A1 (zh) * | 2011-10-10 | 2016-05-13 | H. Lundbeck A/S | 具有咪唑并吡嗪骨架pde9i |
| US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
| RU2014123352A (ru) | 2011-11-09 | 2015-12-20 | Эббви Дойчланд Гмбх Унд Ко. Кг | Гетероциклические карбоксамиды, полезные в качестве ингибиторов фосфодиэстеразы типа 10а |
| HK1199879A1 (en) | 2012-01-26 | 2015-07-24 | H.隆德贝克有限公司 | Pde9 inhibitors with imidazo triazinone backbone |
| PE20142258A1 (es) | 2012-04-25 | 2015-01-15 | Takeda Pharmaceutical | Compuesto heterociclico nitrogenado |
| NZ702239A (en) * | 2012-06-19 | 2017-01-27 | Sunovion Pharmaceuticals Inc | Heteroaryl compounds and methods of use thereof |
| WO2014010732A1 (ja) | 2012-07-13 | 2014-01-16 | 武田薬品工業株式会社 | 複素環化合物 |
| US20140045856A1 (en) * | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
| US9464085B2 (en) | 2012-08-17 | 2016-10-11 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
| IN2015DN01900A (OSRAM) | 2012-09-17 | 2015-08-07 | Abbvie Deutschland | |
| WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| US9790203B2 (en) | 2012-11-26 | 2017-10-17 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| US9200005B2 (en) | 2013-03-13 | 2015-12-01 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
| EP2970258B1 (en) | 2013-03-14 | 2018-04-18 | AbbVie Deutschland GmbH & Co KG | Novel inhibitor compounds of phosphodiesterase type 10a |
| EP2975031A4 (en) | 2013-03-14 | 2017-04-19 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EP3018126A4 (en) | 2013-07-03 | 2016-12-07 | Takeda Pharmaceuticals Co | HETEROCYCLIC CONNECTION |
| WO2015002230A1 (ja) | 2013-07-03 | 2015-01-08 | 武田薬品工業株式会社 | アミド化合物 |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| CN103980281B (zh) * | 2014-05-27 | 2016-06-08 | 天津市斯芬克司药物研发有限公司 | 一种咪唑吡嗪化合物及其制备方法 |
| LT3865484T (lt) | 2015-07-07 | 2024-02-12 | H. Lundbeck A/S | Pde9 inhibitorius su imidazopirazinono karkasu, skirtas periferinių ligų gydymui |
| HRP20240363T1 (hr) | 2018-05-25 | 2024-06-07 | Cardurion Pharmaceuticals, Inc. | Monohidratni i kristalni oblici 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirolidin-3-il]-3-tetrahidropiran-4-il-7h-imidazo [1,5-a] pirazin-8-ona |
| WO2020047311A1 (en) | 2018-08-31 | 2020-03-05 | Imara Inc. | Pde9 inhibitors for treating sickle cell disease |
| JP2022501335A (ja) | 2018-09-28 | 2022-01-06 | 武田薬品工業株式会社 | 自閉症スペクトラム障害を治療または予防するためのバリポデクト（Ｂａｌｉｐｏｄｅｃｔ） |
| CN114524808B (zh) * | 2022-02-21 | 2023-10-24 | 深圳市儿童医院 | 一种吡唑衍生物及其作为pde10抑制剂的用途 |
| CN114524806B (zh) * | 2022-02-22 | 2024-09-03 | 深圳市儿童医院 | 一种三氮唑衍生物及其作为pde10抑制剂的用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2322311C (en) * | 1998-03-04 | 2009-10-13 | Bristol-Myers Squibb Company | Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors |
| JPH11292878A (ja) * | 1998-04-09 | 1999-10-26 | Yamanouchi Pharmaceut Co Ltd | イミダゾナフチリジン誘導体 |
| US20030032579A1 (en) * | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| IL149106A0 (en) * | 2001-04-20 | 2002-11-10 | Pfizer Prod Inc | Therapeutic use of selective pde10 inhibitors |
| TW200817400A (en) * | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
-
2007
- 2007-05-18 TW TW096117904A patent/TW200815436A/zh unknown
- 2007-05-24 US US11/753,260 patent/US20070299079A1/en not_active Abandoned
- 2007-05-29 JP JP2009512481A patent/JP2009538852A/ja active Pending
- 2007-05-29 AU AU2007267391A patent/AU2007267391A1/en not_active Abandoned
- 2007-05-29 MX MX2008015308A patent/MX2008015308A/es not_active Application Discontinuation
- 2007-05-29 AR ARP070102308A patent/AR060984A1/es unknown
- 2007-05-29 WO PCT/EP2007/004747 patent/WO2007137819A1/en not_active Ceased
- 2007-05-29 BR BRPI0711857-0A patent/BRPI0711857A2/pt not_active IP Right Cessation
- 2007-05-29 EP EP07725638A patent/EP2021341A1/en not_active Withdrawn
- 2007-05-29 CN CNA2007800178341A patent/CN101448829A/zh active Pending
- 2007-05-29 CA CA002653412A patent/CA2653412A1/en not_active Abandoned
- 2007-05-30 PE PE2007000675A patent/PE20080266A1/es not_active Application Discontinuation
- 2007-05-30 CL CL2007001555A patent/CL2007001555A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009538852A5 (OSRAM) | ||
| EP3317289B1 (en) | Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection | |
| JP6236173B2 (ja) | 脊髄性筋萎縮症を処置するための化合物 | |
| AU2016256728B2 (en) | Thiadiazole analogs thereof and methods for treating smn-deficiency-related-conditions | |
| JP5658664B2 (ja) | １，２−二置換複素環式化合物 | |
| CA2866143C (en) | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | |
| CN115448910A (zh) | 一种哒嗪类衍生物抑制剂、其制备方法和应用 | |
| US20090239874A1 (en) | Pyrido[3,2-e]pyrazines, their use as inhibitors of phospohodiesterase 10, and processes for preparing them | |
| JP2009538853A5 (OSRAM) | ||
| US20070299079A1 (en) | 4-AMINO-PYRIDO[3,2-e]PYRAZINES, THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10, AND PROCESSES FOR PREPARING THEM | |
| JP6600319B2 (ja) | ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法 | |
| CN102164604A (zh) | 用作激酶调节剂的稠合杂环化合物 | |
| CN106008479B (zh) | 作为磷脂酰肌醇3-激酶δ抑制剂的取代嘧啶类化合物及其应用 | |
| AU2013355054B2 (en) | Diazole lactams | |
| CN108137539B (zh) | 取代的苯并咪唑、它们的制备和它们作为药物的用途 | |
| JP2020532585A (ja) | インターフェロン遺伝子刺激因子調節薬としての環状ジヌクレオチド | |
| RS63581B1 (sr) | Inhibitori p38 kinaze smanjuju ekspresiju dux4 i nizvodnih gena u cilju lečenja fshd | |
| CN105936635B (zh) | 作为磷脂酰肌醇3-激酶δ抑制剂的化合物及其应用 | |
| CN102388055A (zh) | 咪唑并[2,1-b][1,3,4]噻二唑衍生物 | |
| AU2011258005A1 (en) | Heterocyclic compounds as Janus kinase inhibitors | |
| RS52838B (sr) | Fenoksimetil heterociklična jedinjenja | |
| CN107108627A (zh) | 作为沉默调节蛋白调节剂的取代的桥环脲类似物 | |
| CA2935985A1 (en) | Organic compounds | |
| CN106414459B (zh) | 作为pde1抑制剂的六氢呋喃并吡咯 | |
| CN105985354B (zh) | 嘧啶衍生物、细胞毒性剂、药物组合物及其应用 |